Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis
- PMID: 20054859
- DOI: 10.1002/ppul.21117
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis
Erratum in
- Pediatr Pulmonol. 2010 May;45(5):521-2
Abstract
Rationale: Lung function (FEV(1)) generally improves during treatment of pulmonary exacerbations in patients with cystic fibrosis (CF). However, it is unclear how often return to previous baseline FEV(1) is achieved.
Objectives: (1) To determine the proportion of pediatric patients with CF treated for a pulmonary exacerbation who fail to recover to baseline FEV(1) and (2) to identify factors associated with this failure.
Methods: We performed a case-control analysis of patients from a single pediatric CF center admitted for their first pulmonary exacerbation in 2001-2006. Patients were considered to have recovered to baseline FEV(1) if their best FEV(1) within the 3 months following treatment was >or=95% of the best FEV(1) during the 6 months prior to treatment. Logistic regression was used to estimate associations between clinical characteristics and failure to regain baseline FEV(1).
Results: Of 104 patients, 24 (23.1%) did not recover to baseline FEV(1). The adjusted odds ratio of failure to recover to baseline FEV(1) was 1.49 (95% confidence interval [CI] 1.20, 1.86) for every 5% greater decline in FEV(1) from baseline to admission. In exploratory analyses, the adjusted odds ratios for the failure to recover to baseline were also significantly higher for patients who were evaluated in our CF clinic more frequently between the baseline measurement and admission, were younger, or were insured by Medicaid.
Conclusions: Approximately one in four patients with CF failed to recover to baseline lung function after a pulmonary exacerbation despite treatment with intravenous antibiotics. Failure to recover to baseline was associated with the degree of decline in FEV(1) that had occurred prior to hospital admission, suggesting opportunities for earlier intervention to improve lung function outcomes. Additional studies are needed to determine how the failure to recover to baseline affects subsequent FEV(1) decline.
(c) 2010 Wiley-Liss, Inc.
Similar articles
-
Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.Am J Respir Crit Care Med. 2010 Sep 1;182(5):627-32. doi: 10.1164/rccm.200909-1421OC. Epub 2010 May 12. Am J Respir Crit Care Med. 2010. PMID: 20463179 Free PMC article.
-
Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.J Cyst Fibros. 2012 Jan;11(1):8-13. doi: 10.1016/j.jcf.2011.07.008. Epub 2011 Aug 16. J Cyst Fibros. 2012. PMID: 21849265
-
Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.Pediatr Pulmonol. 2011 Apr;46(4):393-400. doi: 10.1002/ppul.21374. Epub 2010 Oct 21. Pediatr Pulmonol. 2011. PMID: 20967845
-
Acute Pulmonary Exacerbations in Cystic Fibrosis.Semin Respir Crit Care Med. 2019 Dec;40(6):792-803. doi: 10.1055/s-0039-1697975. Epub 2019 Oct 28. Semin Respir Crit Care Med. 2019. PMID: 31659730 Free PMC article. Review.
-
Systematic review and meta-analysis: Associations of vitamin D with pulmonary function in children and young people with cystic fibrosis.Clin Nutr ESPEN. 2023 Apr;54:349-373. doi: 10.1016/j.clnesp.2023.02.006. Epub 2023 Feb 10. Clin Nutr ESPEN. 2023. PMID: 36963882
Cited by
-
Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials.Microorganisms. 2023 Mar 31;11(4):916. doi: 10.3390/microorganisms11040916. Microorganisms. 2023. PMID: 37110338 Free PMC article. Review.
-
Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.Eur Respir J. 2025 Aug 8;66(2):2402443. doi: 10.1183/13993003.02443-2024. Print 2025 Aug. Eur Respir J. 2025. PMID: 40506211 Free PMC article. Clinical Trial.
-
The role of the microbiome in exacerbations of chronic lung diseases.Lancet. 2014 Aug 23;384(9944):691-702. doi: 10.1016/S0140-6736(14)61136-3. Lancet. 2014. PMID: 25152271 Free PMC article. Review.
-
Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis.Pediatr Pulmonol. 2025 Mar;60(3):e71019. doi: 10.1002/ppul.71019. Pediatr Pulmonol. 2025. PMID: 40018992
-
C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations.J Pulm Respir Med. 2016 Oct 14;6(5):1000375. doi: 10.4172/2161-105X.1000375. J Pulm Respir Med. 2016. PMID: 28066689 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical